BidaskClub lowered shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a strong-buy rating to a buy rating in a research note released on Saturday.
Other equities analysts have also issued research reports about the company. HC Wainwright set a $12.00 price target on Pieris Pharmaceuticals and gave the company a buy rating in a research report on Friday, February 9th. ValuEngine upgraded Pieris Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, February 2nd. Finally, William Blair began coverage on Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They issued an outperform rating for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $10.00.
Pieris Pharmaceuticals (PIRS) opened at $8.63 on Friday. Pieris Pharmaceuticals has a 1 year low of $1.88 and a 1 year high of $9.75. The firm has a market capitalization of $433.27, a price-to-earnings ratio of -11.66 and a beta of 1.74.
A number of institutional investors have recently made changes to their positions in PIRS. Voya Investment Management LLC purchased a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $100,000. Wells Fargo & Company MN purchased a new stake in Pieris Pharmaceuticals in the 3rd quarter worth about $105,000. Cetera Advisor Networks LLC purchased a new stake in Pieris Pharmaceuticals in the 4th quarter worth about $124,000. Bank of Montreal Can purchased a new stake in Pieris Pharmaceuticals in the 4th quarter worth about $144,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares in the last quarter. 50.10% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “BidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to Buy” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/18/bidaskclub-downgrades-pieris-pharmaceuticals-pirs-to-buy.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.